Ranibizumab interactions

Conditions

Conditions in which Ranibizumab needs care, as documented in this source.

• Eye Infections

  Major

  Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.

  4 sources

  1. "Product Information. Macugen (pegaptanib ophthalmic)." OSI Pharmaceuticals Inc (2004):
  2. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech (2006):
  3. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc (2011):
  4. "Product Information. Vabysmo (faricimab ophthalmic)." Genentech (2022):

• Ocular Hypertension

  Moderate

  Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.

  1 source

  1. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech (2006):